These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28330604)

  • 61. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.
    Garcia AG; Nedev H; Bijian K; Su J; Alaoui-Jamali MA; Saragovi HU
    Oncogene; 2013 May; 32(20):2527-33. PubMed ID: 22797066
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HER2 targeted polyplexes: the effect of polyplex composition and conjugation chemistry on in vitro and in vivo characteristics.
    Germershaus O; Neu M; Behe M; Kissel T
    Bioconjug Chem; 2008 Jan; 19(1):244-53. PubMed ID: 18034452
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Utilizing Solid-Phase to Enable High-Throughput, Site-Specific Conjugation and Dual-Labeled Antibody and Fab Conjugates.
    Puthenveetil S
    Methods Mol Biol; 2020; 2078():99-112. PubMed ID: 31643052
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
    Lin K; Tibbitts J; Shen BQ
    Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.
    Patel VF; Hardin JN; Mastro JM; Law KL; Zimmermann JL; Ehlhardt WJ; Woodland JM; Starling JJ
    Bioconjug Chem; 1996; 7(4):497-510. PubMed ID: 8853464
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
    Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
    Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation.
    Elledge SK; Tran HL; Christian AH; Steri V; Hann B; Toste FD; Chang CJ; Wells JA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5733-5740. PubMed ID: 32123103
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.
    Junttila TT; Parsons K; Olsson C; Lu Y; Xin Y; Theriault J; Crocker L; Pabonan O; Baginski T; Meng G; Totpal K; Kelley RF; Sliwkowski MX
    Cancer Res; 2010 Jun; 70(11):4481-9. PubMed ID: 20484044
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Profiling antibody drug conjugate positional isomers: a system-of-equations approach.
    Le LN; Moore JM; Ouyang J; Chen X; Nguyen MD; Galush WJ
    Anal Chem; 2012 Sep; 84(17):7479-86. PubMed ID: 22913809
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
    Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
    Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antibody-drug conjugates for the treatment of cancer.
    Flygare JA; Pillow TH; Aristoff P
    Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antibody-drug conjugates.
    Ornes S
    Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13695. PubMed ID: 23964113
    [No Abstract]   [Full Text] [Related]  

  • 75. A chemoselective strategy for late-stage functionalization of complex small molecules with polypeptides and proteins.
    Cohen DT; Zhang C; Fadzen CM; Mijalis AJ; Hie L; Johnson KD; Shriver Z; Plante O; Miller SJ; Buchwald SL; Pentelute BL
    Nat Chem; 2019 Jan; 11(1):78-85. PubMed ID: 30397320
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts.
    Pedzisa L; Li X; Rader C; Roush WR
    Org Biomol Chem; 2016 Jun; 14(22):5141-7. PubMed ID: 27184239
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current approaches for the purification of antibody-drug conjugates.
    Matsuda Y
    J Sep Sci; 2022 Jan; 45(1):27-37. PubMed ID: 34473399
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates.
    Thomas JD; Hofer T; Rader C; Burke TR
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5785-8. PubMed ID: 18922692
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans.
    Adumeau P; Sharma SK; Brent C; Zeglis BM
    Mol Imaging Biol; 2016 Feb; 18(1):1-17. PubMed ID: 26754790
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates.
    Ritchie M; Tchistiakova L; Scott N
    MAbs; 2013; 5(1):13-21. PubMed ID: 23221464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.